

Please type a plus sign (+) inside this box →



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

1

of

2

Complete if Known

Application Number	10/631,011
Filing Date	July 31, 2003
First Named Inventor	Markus BERGER et al.
Group Art Unit	1626
Examiner Name	SOLOLA, Taofiq A.
Attorney Docket Number	Sch-2049

U.S. PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Number	Kind Code ² (if known)		
YD	001	6,864,330		Schneider et. At.	March 8, 2005
J	002	2004/0242854		Osborn et al.	December 2, 2004

FOREIGN PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁵
		Office ³	Number ⁴	Kind Code ² (if known)				
YD	003	EP	0121350		SMITHKLINE BECKMAN	10-10-1984		
J	004	WO	03/005026		AMERSHAM BIOSCIENCES ET AL.	01-16-2003		002
J	005	EP	1156053		NAT STARCH CHEM	11-21-2001		
J	006	WO	94/11021		CORTECH INC	05-26-1994		
*	007	DE	10041221		DEUTESCHES KREBSFORCH	03-14-2002		001
YD	008	WO	01/64650		SLOAN KETTERING INST CANCER ET AL.	09-07-2001		
J	009	WO	01/92255		KOSAN BIOSCIENCES INC ET AL.	12-06-2001		
J	010	WO	01/83800		KOSAN BIOSCIENCES INC ET AL.	11-08-2001		

* Not translated.

Examiner
Signature

T. A. Solola

Date
Considered

6-14-06

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached. Number refers to English language corresponding family member.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner of Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



Please type a plus sign (+) inside this box →

+

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 2 of 2

Complete If Known

Application Number	10/631,011
Filing Date	July 31, 2003
First Named Inventor	Markus BERGER et al.
Group Art Unit	1626
Examiner Name	SOLOLA, Taofiq A.
Attorney Docket Number	Sch-2049

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
Y0	011	BERSUKER I B ET AL: "IMPROVED ELECTRON-CONFORMATIONAL METHOD OF PHARMACOPHORE IDENTIFICATION AND BIOACTIVITY PREDICTION. APPLICATION TO ANGIOTENSIN CONVERTING ENZYME INHIBITORS" JOURNAL OF CHEMICAL INFORMATION AND COMPUTER SCIENCES. 2000 NOV-DEC, vol. 40, NO. 6, November 2000 pages 1363-1376	
	012	WANG LAI-XI ET AL: "CARBOHYDRATE-CENTERED MALEIMIDE CLUSTER AS A NEW TYPE OF TEMPLATES FOR MULTIVALENT PEPTIDE ASSEMBLING: SYNTHESIS OF MULTIVALENT HIV-1 gp41 PEPTIDES." BIOORGANIC AND MEDICINAL CHEMISTRY, vol. 11, no. 1, 2 January 2003, pages 159-166	
	013	REGHUNADHAN NAIR C P ET AL.: "FREE RADICAL COPOLYMERISATION OF N-(4-HYDROXY PHENYL) MALEIMIDE WITH VINYL MONOMERS: SOLVENT AND PENULTIMATE-UNIT EFFECTS" EUROPEAN POLYMER JOURNAL, PERGAMON PRESS LTD. OXFORD, GB., vol. 35, no. 10, 28 July 1999, pages 1829-1840	
✓	014	KALGUTKAR A S ET AL.: "INACTIVATION OF PROSTAGLANDIN ENDOPEROXIDE SYNTHASE (PGHS) BY N-(SUBSTITUTED) MALEIMIDES" ADVANCES IN EXPERIMENTAL MEDICINE AND BIOLOGY. 1997, vol. 407, 1997, pages 79-85	

Examiner
Signature

T. A. Solola

Date

Considered

6-14-06

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner of Patents, P.O. Box 1450, Alexandria, VA 22313-1450.